Ferhatpaşa Mah. 24. Sok. No:70 Ataşehir-İstanbul
Telefon Faks
0216 573 2591/96 0216 573 0883
Moleküler ve Genetik
BCR-ABL1 Mutasyon Testi
Mutations in BCR-ABL1 are responsible for the majority of cases of resistance to tyrosine kinase inhibitor therapies in chronic myelogenous leukemia and Ph+ ALL. MolecularMD’s set of bi-directional Sanger sequencing assays identifies mutations in both p210 and p190 BCR-ABL1 transcripts covering an extended region including kinase and SH2-SH3 regulatory domains, enabling detection of over 40 documented amino acid substitutions including the T315I mutation